Finance entity
MarketBeat.com is most often covered alongside Wall Street Zen, which appears in 5 of these 8 stories. The 12-day window averages about 4.7 stories each week. The busiest single day carried 3. Coverage clusters in markets, which accounts for 6 of those 8, with the remainder spread across 1 other category.
Last mentioned: Aug 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
MarketBeat.com is most often covered alongside Wall Street Zen, which appears in 5 of these 8 stories. The 12-day window averages about 4.7 stories each week. The busiest single day carried 3. Coverage clusters in markets, which accounts for 6 of those 8, with the remainder spread across 1 other category. Negative sentiment reaches 0% here, compared with 16% across the 317-story beat baseline for the same window. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 5.7 in the same window. MarketBeat.com appears in 8 tracked Finance stories published from August 13, 2026 through August 24, 2026.
Computed from the 8 stories linked to this entity, with beat comparisons drawn from all 317 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MarketBeat.com. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen upgrades both stocks
Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
Friday trading close
AMPY opened at $4.78 and BRSP opened at $5.00.
Benchmark and Weiss update AMPY
Benchmark cut the AMPY target to $9.00 from $11.00 with a buy rating; Weiss raised AMPY from sell(d) to sell(d+).
Wall Street Zen downgrades to Hold
Wall Street Zen cut both Klaviyo and Oceaneering International from Buy to Hold in Saturday research notes.
Citigroup lifts KVYO target
Citigroup raised its Klaviyo price target from $34.00 to $36.00 with a Buy rating.
KVYO analyst revisions
Stephens, BTIG, Stifel, and Truist adjusted price targets on Klaviyo following earnings.
Klaviyo Q2 earnings
Klaviyo reported EPS of $0.19, meeting consensus, and revenue of $370.58 million.
OII insider sale
SVP Christopher J. Dyer sold 1,200 OII shares at an average price of $47.65 for $57,180.
B. Riley trims BRSP target
B. Riley Financial lowered its BrightSpire Capital target from $7.00 to $6.50 with a buy rating.
JonesTrading reiterates BRSP buy
JonesTrading reissued a buy rating and a $6.50 price objective on BrightSpire Capital.
Weiss upgrades OII
Weiss Ratings raised OII from Buy (B-) to Buy (B).
BrightSpire reports Q2 earnings
BRSP posted EPS of $0.13, missing the $0.15 consensus, with revenue of $48.70 million.
Barclays lifts OII target
Barclays increased its OII price objective from $39.00 to $47.00 with an Equal Weight rating.
James Frew buys AMPY shares
Insider James Frew acquired 25,000 Amplify Energy shares at an average cost of $3.95 per share.
Citigroup raises OII target
Citigroup raised its Oceaneering target from $35.00 to $40.00 with a Neutral rating.
Weiss lowers BrightSpire Capital
Weiss Ratings lowered BRSP from hold (c-) to sell (d+).
TD Cowen lifts OII target
TD Cowen raised its Oceaneering International price target from $34.00 to $36.00 with a Hold rating.
BTIG upgrades BrightSpire Capital
BTIG Research raised BRSP from neutral to buy and set a $7.00 price target.
A Sunday analyst action shifted two healthcare microcaps from Sell to Hold. CTNM carries a $646.69M valuation and a $20.25 consensus target, while ENVB trades at $1.43 with a $6.41M market cap and negative P/E.
Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Source: dailypolitical.com · tickerreport.com
Analysts remain mostly bullish on RTX and GE Vernova after July earnings, lifting price targets to as high as $250 and $1,338 respectively. Friday's gains came on unusually light volume, raising questions about conviction. Finance readers get a breakdown of target upside, valuation, and risk metrics.
Source: tickerreport.com · dailypolitical.com
A MarketBeat-based comparison shows ZOOZ Power offers 85.01% implied upside versus Regal Rexnord's 39.62%, but the ownership and volatility profiles point in opposite directions. Regal Rexnord wins on 9 of 12 factors, yet ZOOZ's insider-heavy ownership and analyst target suggest a higher-reward, lower-liquidity opportunity.
Source: Ticker Report · Watch List News
Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Morgan Stanley trimmed its American Homes 4 Rent target to $38 from $38.50 while keeping an Overweight rating, against a $36.78 consensus and Moderate Buy average. Equity research actions from Jefferies, UBS, RBC, Mizuho, and Compass Point reveal a broadly constructive but price-sensitive stance on the REIT.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen downgraded both Oceaneering International and Klaviyo from Buy to Hold, spotlighting two $5 billion market-cap companies with vastly different P/E ratios—14.59 for OII and 895.95 for KVYO. The ratings actions come as consensus targets diverge from current prices.
Source: dailypolitical.com · themarketsdaily.com
MarketBeat.com is linked from 8 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
